Q4 2024 J B Chemicals and Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- J.B. Chemicals & Pharmaceuticals Ltd (BOM:506943) reported a healthy revenue growth of 13% year-on-year for Q4 FY24, reaching INR862 crores.
- Gross profit margins expanded by 130 basis points in Q4 FY24 to 65.2%, and by 320 basis points for the full year to 66.1%.
- The company is now net cash positive, with a significant reduction in gross debt from INR548 crores to INR357 crores year-on-year.
- The domestic business showed strong performance, growing by 22% in Q4 and 16% for the full year, driven by a robust brand portfolio and higher share of chronic products.
- The CDMO business grew by 9% year-on-year in Q4 and entered the European market, showing promising future growth potential.
- The international business was impacted by strategic choices in the South Africa market, leading to a lower reported growth of 4% in Q4.
- The ophthalmology portfolio, despite integration, is expected to have limited gross margins in the short term, potentially impacting overall profitability.
- Higher other expenses were noted during the quarter due to one-off integration costs and increased freight costs.
- The acute business faced challenges due to a muted season, impacting overall growth.
- The competitive intensity in the heart failure segment has increased, putting pressure on the market share of key brands like Azmarda.
Ladies and gentlemen, good day, and welcome to the J.B. Pharma's Q4 FY24 earnings conference call as on May 21, 2024. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Jason D'souza, Executive Vice President at J.B. Pharma. Thank you, and over to you, sir.
' -
Thank you, Dorwin. Welcome to the earnings call of J.B. Pharma. We have with us today, Nikhil Chopra, CEO and Whole Time Director; Kunal Khanna, President, Operations; and Narayan Saraf, the CFO at J.B. Chemicals & Pharmaceuticals Limited.
Before we begin, I would like to state that some of the statements in today's discussion may be forward-looking in nature and may involve certain risks and uncertainties. A detailed statement in this regard is available in the Q4 results presentation that has been sent to you earlier. I would like to now hand over the floor to Mr. Nikhil Chopra to begin the proceedings for the call and give us his opening comments
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
